Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. and EU Regulators and Industry Grappling with Track-and-trace Standards to Combat Drug Counterfeiting

This article was originally published in The Gold Sheet

Executive Summary

Pharmaceutical industry groups and lawmakers in the U.S. and the EU are continuing to grapple with what a pharmaceutical track-and-trace system will look like to thwart drug counterfeiting. The EU has three different track-and-trace models with various levels of traceability in each, while in the U.S., efforts to attach a national traceability system to the user fee legislation failed to garner consensus on the best approach, and meanwhile industry is instituting brand protection programs.

You may also be interested in...

Drug Manufacturers Get the Anti-Counterfeiting Law They Wanted: Now They Must Meet Deadlines

November signing of Drug Quality and Security Act into law sets in motion a deadline-packed three-phase process of establishing tracing and serialization requirements for drug products to protect the U.S. market from counterfeits.

The Anti-Falsification Directive: Europe’s Answer to Global Supply Chain Threats

The European Union July 1 published its directive on falsified medicines, setting into motion a tightening of Europe’s pharmaceutical supply chain that will for the most part take place over the next 18 months – and that could cost pharmaceutical companies billions of Euros.

EFPIA Starts Traceability Pilot Program to Combat Drug Counterfeiting

Anti-counterfeiting traceability pilot under way in Europe.

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts